Rapport Therapeutics (NASDAQ:RAPP) Trading Down 10.5% – What’s Next?

Rapport Therapeutics (NASDAQ:RAPP)’s stock price fell 10.5% during mid-day trading on Thursday . The company traded as low as $24.03 and last traded at $24.03. 36,385 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 166,587 shares. The stock had previously closed at $26.84.

Rapport Therapeutics Stock Up 0.4 %

The company’s 50-day moving average price is $21.90.

Rapport Therapeutics (NASDAQ:RAPP) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($1.02). On average, equities analysts forecast that Rapport Therapeutics will post -3.46 earnings per share for the current year.

Institutional Investors Weigh In On Rapport Therapeutics

Several large investors have recently modified their holdings of the stock. Values First Advisors Inc. purchased a new stake in Rapport Therapeutics in the third quarter worth $31,000. SG Americas Securities LLC bought a new position in Rapport Therapeutics during the third quarter worth about $101,000. Sandia Investment Management LP purchased a new position in shares of Rapport Therapeutics in the second quarter worth about $116,000. Davidson Kempner Capital Management LP bought a new stake in shares of Rapport Therapeutics in the second quarter valued at approximately $229,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Rapport Therapeutics during the 2nd quarter valued at approximately $380,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.